Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical care
No Thumbnail Available
Authors
Moreno-Olmedo,Elena;Owczarczyk,Kasia;Chadwick,Eliot;Dickinson,Peter;Duffton,Aileen;Jones,Bleddyn;Good,James S.;McDonald,Fiona;Murray,Louise J.;Rackley,Thomas;Robinson,Maxwell;Sinclair,Judith;Strawson-Smith,Thomas;Tree,Alison;Tsang,Yat Man;Zarkar,Anjali;Dean,Christopher;DÃez,Patricia;Williams,Matt;Andratschke,Nicholas;Muirhead,Rebecca
Check for full-text access
Issue Date
2025
Type
Article
Language
Keywords
Alternative Title
Abstract
Stereotactic ablative body radiotherapy (SABR) is routinely used for the management of oligometastatic disease. Increasingly, there is overlap of targets or organs at risk with previous radiotherapy fields. As substantial variation in delivery of clinical practice exists, the UK SABR Consortium worked with a collaborative national group to develop pelvic SABR re-irradiation consensus guidelines. The scope of the guidance includes patient selection criteria, pre-treatment considerations, delineation guidelines, dose prescription, calculations of cumulative dose constraints, and optimal planning technique. This guidance is part of an ongoing national prospective audit in collaboration with the Royal College of Radiologists and EORTC ReCare.
Description
Citation
Publisher
License
Journal
Technical innovations & patient support in radiation oncology
Volume
35